Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Clin Chim Acta ; 448: 86-90, 2015 Aug 25.
Article in English | MEDLINE | ID: mdl-26123581

ABSTRACT

The diagnosis of urinary tract infection (UTI) by urine culture is a time-consuming and costly procedure. Usage of a screening method, to identify negative samples, would therefore affect time-to-diagnosis and laboratory cost positively. Urine flow cytometers are able to identify particles in urine. Together with the introduction of a cut-off value, which determines if a urine sample is subsequently cultured or not, the number of cultures can be reduced, while maintaining a low level of false negatives and a high negative predictive value. Recently, Sysmex developed additional software for their urine flow cytometers. Besides measuring the number of bacteria present in urine, information is given on bacterial morphology, which may guide the physician in the choice of antibiotic. In this study, we evaluated this software update. The UF1000i classifies bacteria into two categories: 'rods' and 'cocci/mixed'. Compared to the actual morphology of the bacterial pathogen found, the 'rods' category scores reasonably well with 91% chance of classifying rod-shaped bacteria correctly. The 'cocci/mixed' category underperforms, with only 29% of spherical-shaped bacteria (cocci) classified as such. In its current version, the bacterial morphology software does not classify bacteria, according to their morphology, well enough to be of clinical use in this study population.


Subject(s)
Flow Cytometry/methods , Gram-Positive Cocci/classification , Gram-Positive Cocci/isolation & purification , Urinary Tract Infections/diagnosis , Urinary Tract Infections/urine , Urine/microbiology , Anti-Bacterial Agents/pharmacology , Female , Gram-Positive Cocci/drug effects , Humans , Male , Software , Urinary Tract Infections/microbiology
2.
Eur J Clin Microbiol Infect Dis ; 31(7): 1575-83, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22080416

ABSTRACT

Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) is a fast and reliable method for the identification of bacteria from agar media. Direct identification from positive blood cultures should decrease the time to obtaining the result. In this study, three different processing methods for the rapid direct identification of bacteria from positive blood culture bottles were compared. In total, 101 positive aerobe BacT/ALERT bottles were included in this study. Aliquots from all bottles were used for three bacterial processing methods, i.e. the commercially available Bruker's MALDI Sepsityper kit, the commercially available Molzym's MolYsis Basic5 kit and a centrifugation/washing method. In addition, the best method was used to evaluate the possibility of MALDI application after a reduced incubation time of 7 h of Staphylococcus aureus- and Escherichia coli-spiked (1,000, 100 and 10 colony-forming units [CFU]) aerobe BacT/ALERT blood cultures. Sixty-six (65%), 51 (50.5%) and 79 (78%) bottles were identified correctly at the species level when the centrifugation/washing method, MolYsis Basic 5 and Sepsityper were used, respectively. Incorrect identification was obtained in 35 (35%), 50 (49.5%) and 22 (22%) bottles, respectively. Gram-positive cocci were correctly identified in 33/52 (64%) of the cases. However, Gram-negative rods showed a correct identification in 45/47 (96%) of all bottles when the Sepsityper kit was used. Seven hours of pre-incubation of S. aureus- and E. coli-spiked aerobe BacT/ALERT blood cultures never resulted in reliable identification with MALDI-TOF MS. Sepsityper is superior for the direct identification of microorganisms from aerobe BacT/ALERT bottles. Gram-negative pathogens show better results compared to Gram-positive bacteria. Reduced incubation followed by MALDI-TOF MS did not result in faster reliable identification.


Subject(s)
Bacteremia/diagnosis , Bacteria/classification , Bacteria/isolation & purification , Bacteriological Techniques/methods , Blood/microbiology , Specimen Handling/methods , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Humans , Time Factors
3.
Eur J Clin Microbiol Infect Dis ; 30(3): 337-42, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20972809

ABSTRACT

To accelerate differentiation between Staphylococcus aureus and coagulase-negative staphylococci (CNS), this study aimed to compare six different DNA extraction methods from two commonly used blood culture materials, i.e. BACTEC and BacT/ALERT. Furthermore, we analysed the effect of reduced blood culture incubation for the detection of staphylococci directly from blood culture material. A real-time polymerase chain reaction (PCR) duplex assay was used to compare the six different DNA isolation protocols on two different blood culture systems. Negative blood culture material was spiked with methicillin-resistant S. aureus (MRSA). Bacterial DNA was isolated with automated extractor easyMAG (three protocols), automated extractor MagNA Pure LC (LC Microbiology Kit M(Grade)), a manual kit MolYsis Plus and a combination of MolYsis Plus and the easyMAG. The most optimal isolation method was used to evaluate reduced bacterial incubation times. Bacterial DNA isolation with the MolYsis Plus kit in combination with the specific B protocol on the easyMAG resulted in the most sensitive detection of S. aureus, with a detection limit of 10 CFU/ml, in BacT/ALERT material, whereas using BACTEC resulted in a detection limit of 100 CFU/ml. An initial S. aureus or CNS load of 1 CFU/ml blood can be detected after 5 h of incubation in BacT/ALERT 3D by combining the sensitive isolation method and the tuf LightCycler assay.


Subject(s)
Blood/microbiology , DNA, Bacterial/isolation & purification , Staphylococcal Infections/diagnosis , Staphylococcus aureus/classification , Bacteriological Techniques , Coagulase/metabolism , Humans , Polymerase Chain Reaction , Staphylococcal Infections/microbiology , Staphylococcus/classification , Staphylococcus/genetics , Staphylococcus/isolation & purification , Staphylococcus aureus/genetics , Staphylococcus aureus/isolation & purification
4.
N Engl J Med ; 360(1): 20-31, 2009 Jan 01.
Article in English | MEDLINE | ID: mdl-19118302

ABSTRACT

BACKGROUND: Selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) are infection-prevention measures used in the treatment of some patients in intensive care, but reported effects on patient outcome are conflicting. METHODS: We evaluated the effectiveness of SDD and SOD in a crossover study using cluster randomization in 13 intensive care units (ICUs), all in The Netherlands. Patients with an expected duration of intubation of more than 48 hours or an expected ICU stay of more than 72 hours were eligible. In each ICU, three regimens (SDD, SOD, and standard care) were applied in random order over the course of 6 months. Mortality at day 28 was the primary end point. SDD consisted of 4 days of intravenous cefotaxime and topical application of tobramycin, colistin, and amphotericin B in the oropharynx and stomach. SOD consisted of oropharyngeal application only of the same antibiotics. Monthly point-prevalence studies were performed to analyze antibiotic resistance. RESULTS: A total of 5939 patients were enrolled in the study, with 1990 assigned to standard care, 1904 to SOD, and 2045 to SDD; crude mortality in the groups at day 28 was 27.5%, 26.6%, and 26.9%, respectively. In a random-effects logistic-regression model with age, sex, Acute Physiology and Chronic Health Evaluation (APACHE II) score, intubation status, and medical specialty used as covariates, odds ratios for death at day 28 in the SOD and SDD groups, as compared with the standard-care group, were 0.86 (95% confidence interval [CI], 0.74 to 0.99) and 0.83 (95% CI, 0.72 to 0.97), respectively. CONCLUSIONS: In an ICU population in which the mortality rate associated with standard care was 27.5% at day 28, the rate was reduced by an estimated 3.5 percentage points with SDD and by 2.9 percentage points with SOD. (Controlled Clinical Trials number, ISRCTN35176830.)


Subject(s)
Bacteremia/prevention & control , Cross Infection/prevention & control , Decontamination , Gastrointestinal Tract/microbiology , Oropharynx/microbiology , APACHE , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Critical Illness/mortality , Critical Illness/therapy , Cross Infection/epidemiology , Cross-Over Studies , Female , Gram-Negative Bacteria/isolation & purification , Humans , Infection Control/methods , Intensive Care Units , Logistic Models , Male , Middle Aged , Respiration, Artificial
5.
Neth J Med ; 63(10): 413-6, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16301764

ABSTRACT

We describe a series of twelve patients with a psoas abscess seen in a three-year period in a university hospital and a large teaching hospital in the Netherlands. In our series, five of the 12 patients had a primary psoas abscess. The predisposing conditions were intravenous drug use, diabetes mellitus, prostate carcinoma and haematoma in the psoas muscle in a patient with haemophilia A. Seven of the 12 patients had a secondary psoas abscess. Five cases were due to vertebral osteomyelitis including two cases of tuberculosis. In the other two cases it was due to colitis and urinary tract infection. It is remarkable that in our series there was only one patient with a psoas abscess secondary to a disease of the digestive tract, while this is the most common cause of a secondary psoas abscess in the literature. There were two cases of tuberculosis which is an emerging disease again.


Subject(s)
Psoas Abscess/etiology , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Psoas Abscess/microbiology , Risk Factors , Staphylococcal Infections
6.
Clin Microbiol Infect ; 7(9): 486-91, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11678931

ABSTRACT

OBJECTIVE: To evaluate bacterial susceptibility to linezolid in the Netherlands in comparison with other antibiotics. METHODS: Bacterial strains were isolated between September 1999 and January 2000 from patients presumed to require antibiotic treatment. The in vitro activity of 1226 strains from 34 participating laboratories was tested against linezolid, vancomycin, teicoplanin, oxacillin, penicillin, erythromycin, ampicillin and other antibiotics against enterococci, coagulase-negative staphylococci, Staphylococcus aureus and Streptococcus pneumoniae. Minimal inhibitory concentrations (MIC) were obtained with the E test on Mueller-Hinton agar: every laboratory included control strains. For vancomycin and teicoplanin only, brain-heart infusion agar and an inoculum of 2.0 McFarland was used for Staphylococcus aureus, coagulase-negative staphylococci and enterococci to support a better growth and clear recognition of hetero-resistant colonies. RESULTS: The values of MIC90 for linezolid were 1.5, 0.75, 0.75 and 1 mg/L for Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pneumoniae and enterococci, respectively. Six enterococcal strains with decreased susceptibility against vancomycin or teicoplanin were identified as Enterococcus faecium, E. gallinarum and E. casseliflavus (two strains each) and they were found to harbor vanA, vanC1 and vanC2/3 genes, respectively. Nine per cent of Streptococcus pneumoniae (an increase from 1% 4 years ago) showed decreased susceptibility to erythromycin, of both the ermB and mefE type; there was no cross-resistance with linezolid. Twelve coagulase-negative staphylococcal strains were resistant to teicoplanin. CONCLUSION: Linezolid is a promising drug in the treatment of infections caused by Gram-positive cocci. Cross-resistance with other antibiotics tested was not found.


Subject(s)
Acetamides/pharmacology , Anti-Bacterial Agents/pharmacology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Cocci/drug effects , Oxazolidinones/pharmacology , Glycopeptides , Humans , Linezolid , Microbial Sensitivity Tests , Netherlands
7.
Clin Infect Dis ; 33(8): e93-6, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11550121

ABSTRACT

A multidrug-resistant strain of Streptococcus pneumoniae was isolated in The Netherlands during a nosocomial outbreak among 36 patients who mainly had chronic obstructive pulmonary disease. After the commencement of barrier nursing and short-term ceftriaxone-rifampin eradication therapy, the epidemic ceased. However, eradication therapy failed in 3 patients, and follow-up investigation of these patients showed the emergence of rifampin-resistant isolates.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial , Pneumococcal Infections/microbiology , Rifampin/pharmacology , Streptococcus pneumoniae/drug effects , Amino Acid Sequence , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Cross Infection/epidemiology , Cross Infection/microbiology , DNA-Directed RNA Polymerases/chemistry , DNA-Directed RNA Polymerases/genetics , Humans , Molecular Sequence Data , Penicillin Resistance , Pneumococcal Infections/drug therapy , Pneumococcal Infections/epidemiology , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/epidemiology , Rifampin/therapeutic use , Streptococcus pneumoniae/genetics
10.
Diabetes Care ; 23(6): 744-9, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10840989

ABSTRACT

OBJECTIVE: To study the prevalence of and risk factors for asymptomatic bacteriuria (ASB) in women with and without diabetes. RESEARCH DESIGN AND METHODS: A total of 636 nonpregnant women with diabetes (type 1 and type 2) who were 18-75 years of age and had no abnormalities of the urinary tract, and 153 women without diabetes who were visiting the eye and trauma outpatient clinic (control subjects) were included. We defined ASB as the presence of at least 10(5) colony-forming units/ml of 1 or 2 bacterial species in a culture of clean-voided midstream urine from an individual without symptoms of a urinary tract infection (UTI). RESULTS: The prevalence of ASB was 26% in the diabetic women and 6% in the control subjects (P < 0.001). The prevalence of ASB in women with type 1 diabetes was 21%. Risk factors for ASB in type 1 diabetic women included a longer duration of diabetes, peripheral neuropathy, and macroalbuminuria. The prevalence of ASB was 29% in women with type 2 diabetes. Risk factors for ASB in type 2 diabetic women included age, macroalbuminuria, a lower BMI, and a UTI during the previous year. No association was evident between current HbA1c level and the presence of ASB. CONCLUSIONS: The prevalence of ASB is increased in women with diabetes and might be added to the list of diabetic complications in these women.


Subject(s)
Bacteriuria/epidemiology , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 2/complications , Adult , Aged , Albuminuria/epidemiology , Bacteriuria/diagnosis , Diabetes Mellitus, Type 1/microbiology , Diabetes Mellitus, Type 2/microbiology , Female , Glycated Hemoglobin/analysis , Humans , Incidence , Middle Aged , Netherlands/epidemiology , Prevalence , Reference Values , Urinary Tract Infections/epidemiology
11.
J Hosp Infect ; 42(3): 185-92, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10439990

ABSTRACT

Multidrug-resistant strains of Streptococcus pneumoniae were isolated over a two-year period (July 1995 until August 1997) from the sputum of 36 patients who were hospitalized in a Dutch medical centre. Nosocomial transmission was confirmed by typing of the bacterial isolates: all 36 multidrug-resistant isolates shared the same genotype, serotype, and displayed overlapping drug resistance profiles. Thirty-two of the 36 (89%) patients had chronic obstructive pulmonary disease (COPD). The outbreak was initiated by a 76-year old patient, who had been colonized with the same strain since 1993. Because staff screening of the hospital and pulmonary function department was negative, patient-to-patient spread was the most likely cause of this outbreak. The epidemic ceased following the commencement of barrier nursing, a treatment course of ceftriaxone, and a five-day rifampicin eradication therapy for the positive patients. The outbreak resulted from failure to recognize quickly the rapid transmission of this multidrug-resistant pneumococcal clone. We conclude that patients with COPD are at high risk of acquiring multidrug resistant pneumococci, and suggest that COPD patients who are colonized or infected with multidrug-resistant pneumococci should be isolated to prevent future transmission.


Subject(s)
Cross Infection/epidemiology , Disease Outbreaks , Drug Resistance, Microbial , Drug Resistance, Multiple , Pneumococcal Infections/epidemiology , Streptococcus pneumoniae/drug effects , Aged , Carrier State/epidemiology , Cross Infection/microbiology , Disease Outbreaks/statistics & numerical data , Female , Hospitals, Teaching , Humans , Lung Diseases, Obstructive/complications , Lung Diseases, Obstructive/microbiology , Male , Microbial Sensitivity Tests/statistics & numerical data , Middle Aged , Netherlands/epidemiology , Pneumococcal Infections/microbiology , Sputum/microbiology , Streptococcus pneumoniae/isolation & purification
13.
Eur J Clin Microbiol Infect Dis ; 15(11): 861-4, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8997557

ABSTRACT

The minimum inhibitory concentrations of metronidazole and clarithromycin were determined for 780 Helicobacter pylori strains collected in 1994 and 1995 from three different regions in The Netherlands. The overall prevalence of primary metronidazole resistance was 17%, with resistance found more frequently in women (24%) than in men (13%). There was no significant difference between the levels of resistance in the three regions. Primary clarithromycin resistance was rare (1%) and relatively infrequent as compared to that found in other countries. Four of the six strains resistant to clarithromycin were also resistant to metronidazole.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clarithromycin/pharmacology , Drug Resistance, Multiple , Helicobacter pylori/drug effects , Metronidazole/pharmacology , Female , Helicobacter Infections/drug therapy , Helicobacter pylori/isolation & purification , Humans , Male , Microbial Sensitivity Tests , Multicenter Studies as Topic , Netherlands , Prevalence
14.
J Clin Microbiol ; 34(10): 2391-4, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8880486

ABSTRACT

The newly developed fluorescent BACTEC 9000 MB system for automated culture of mycobacteria was compared with the Septi-Chek AFB system and Lowenstein-Jensen medium (LJ). A total of 2,005 clinical specimens were included in the study. Mycobacteria were isolated from 202 (10.1%) specimens, including 155 Mycobacterium tuberculosis complex isolates and 47 Mycobacteria other than M. tuberculosis isolates. Of 131 isolates detected by the BACTEC system, the Septi-Chek AFB system, or both, 120 (91.6%) were detected by the BACTEC system and 105 (80.2%) were detected by the Septi-Chek AFB system (P < 0.02). The recovery rate in the BACTEC system compared with that in the Septi-Chek AFB system was significantly higher for M. tuberculosis complex isolates (P < 0.005) and for isolates from acid-fast smear-negative specimens (P < 0.01). Of 148 isolates detected by the BACTEC system, LJ, or both, 142 (95.9%) were detected by the BACTEC system and 118 (79.9%) were detected by LJ (P < 0.001). The recovery rate in the BACTEC system compared with that on LJ was significantly higher for M. tuberculosis complex isolates (P < 0.001). The BACTEC system detected more mycobacteria from both smear-positive and smear-negative specimens than LJ. The mean times to detection of mycobacteria were 17.6 days for the BACTEC system, 26.0 days for the Septi-Chek AFB system, and 29.4 days for LJ. The BACTEC fluorescent 9000 MB system is a rapid, sensitive, and efficient method for the isolation of mycobacteria.


Subject(s)
Bacterial Typing Techniques , Mycobacterium tuberculosis/classification , Fluorescence , Mycobacterium tuberculosis/isolation & purification
15.
Ned Tijdschr Geneeskd ; 140(2): 94-8, 1996 Jan 13.
Article in Dutch | MEDLINE | ID: mdl-8569928

ABSTRACT

In four patients, men of 64, 66 and 69 years old and a woman of 65 years, who suffered from chronic obstructive pulmonary disease (COPD) and used inhalation corticosteroids in a relatively high dose (800-1600 micrograms of budesonide per day), a pulmonary infection was diagnosed caused by Mycobacterium malmoense (the first two patients) and Aspergillus (the other two) respectively. Inhalation corticosteroids are of great importance in the treatment of asthmatic patients. Their place in the treatment of patients with COPD is much less clear. The patients did not have an immunological deficiency or anatomical pulmonary or bronchial deformation which could have explained the occurrence of these infections. The high dosages of inhalation corticosteroids may have been involved in the cause of these infections by suppressing the T-cell response locally. In view of this, longterm inhalation corticosteroid treatment should be prescribed in COPD patients only if the efficacy of the medication has been proved in the individual patient involved.


Subject(s)
Lung Diseases, Obstructive/drug therapy , Opportunistic Infections/etiology , Respiratory Tract Infections/etiology , Administration, Inhalation , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/adverse effects , Aged , Aspergillosis/diagnosis , Female , Humans , Lung Diseases, Obstructive/complications , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/diagnosis
16.
J Clin Microbiol ; 34(1): 94-7, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8748281

ABSTRACT

We evaluated the performance of three enzyme-linked immunosorbent assays (ELISAs) in detecting serum immunoglobulin G (IgG) and IgA antibodies to Helicobacter pylori; two were new ones from Pyloriset (Pyloriset EIA-G update and Pyloriset EIA-A update; Orion Diagnostica, Espoo, Finland), and the third was the Malakit EIA-G (Biolab, Limal, Belgium). Serum samples from 154 dyspeptic patients were collected. As a reference method, multiple biopsy specimens from different anatomical areas of the stomach were obtained by endoscopy and were analyzed by culture and/or histology and direct urease testing. Accordingly, 126 patients (82%) were found to be H. pylori positive and 28 patients (18%) were found to be H. pylori negative. To validate serology as a predictor of H. pylori infection, sensitivity, specificity, positive and negative predictive values, and accuracy of the assays were calculated against the H. pylori status as determined by the reference method. The corresponding data for the different ELISAs were 100%, 79%, 95%, 100%, and 96% for the Pyloriset ELA-G update, 81%, 89%, 97%, 52%, and 82% for the Pyloriset EIA-A update, and 87%, 86%, 96%, 60%, and 87% for the Malakit EIA-G, respectively. We conclude that the Pyloriset EIA-G update is a reliable and accurate test and that because of its 100% sensitivity, conjunctional IgA testing is not necessary. Its 100% negative predictive value makes it a very useful screening test. For purposes of excluding infection with H. pylori, the performance of the Malakit EIA-G is moderate but can be improved by conjunctional IgA testing. The Pyloriset EIA-A update can be useful as such a conjunctional test.


Subject(s)
Antibodies, Bacterial/blood , Enzyme-Linked Immunosorbent Assay/methods , Gastritis/diagnosis , Helicobacter Infections/diagnosis , Helicobacter pylori/immunology , Helicobacter pylori/isolation & purification , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Enzyme-Linked Immunosorbent Assay/statistics & numerical data , Female , Gastritis/immunology , Gastritis/microbiology , Helicobacter Infections/immunology , Helicobacter Infections/microbiology , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
17.
Neth J Med ; 47(6): 272-7, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8569932

ABSTRACT

BACKGROUND: Our aim was to evaluate a commercially available ELISA (Pyloriset IgG, Orion diagnostica, Imphos B.V.) for detection of serum IgG antibodies to Helicobacter pylori. METHODS: Serum samples were taken from 154 Dutch patients. As a reference method several biopsy specimens were taken from different gastric areas for histological analysis, bacterial culture and direct urease testing. The sensitivity, specificity, positive and negative predictive values of the Pyloriset IgG were calculated as compared to the reference method. RESULTS: Of 154 patients 126 were found to be H. pylori positive (82%), 28 were H. pylori negative (18%). Using a cut-off value at a titre of 500 U/l (as advised by the manufacturer) we found a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 81, 89, 97 and 51%, respectively. Lowering the cut-off value to 350 U/l and excluding patients aged above 70 years optimalized the performance of the Pyloriset IgG to a sensitivity, specificity, PPV and NPV of 92, 96, 99 and 72%, respectively. In the subgroup of 54 patients under the age of 45 years a sensitivity, specificity, PPV and NPV of 92, 100, 100 and 82% was found. CONCLUSIONS: The Pyloriset IgG is a simple and accurate method for detecting H. pylori infection in dyspeptic Dutch patients. The performance of this assay is improved by lowering the cut-off value (test becomes predominantly more sensitive) and excluding older patients (test becomes predominantly more specific). Therefore serology might eventually replace endoscopy or breath tests in the detection of H. pylori infection, especially in the younger age groups.


Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Helicobacter Infections/diagnosis , Helicobacter Infections/immunology , Helicobacter pylori , Immunoglobulin G/blood , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Dyspepsia/microbiology , Female , Helicobacter Infections/complications , Helicobacter Infections/pathology , Humans , Male , Middle Aged , Sensitivity and Specificity
18.
Eur J Gastroenterol Hepatol ; 7(12): 1189-94, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8789310

ABSTRACT

OBJECTIVE: To assess the efficacy and side-effect profile of two currently advocated treatment regimens for eradicating Helicobacter pylori. DESIGN: A randomized, controlled, open, single-centre study. SETTING: A community hospital in The Netherlands. PARTICIPANTS: Seventy-six consecutive patients with (chronic) ulcer disease and biopsy-proven H. pylori infection, but without active ulceration at the time of inclusion. INTERVENTIONS: Patients were randomly allocated to 1 week of quadruple therapy with omeprazole, bismuth, tetracycline and metronidazole (group 1) or 2 weeks of dual therapy with omeprazole and amoxicillin (group 2). Group 1 patients were pretreated with omeprazole for 3 days. MAIN OUTCOME MEASURES: Cure was confirmed by obtaining 10 endoscopic biopsies for urease testing, histology and culture 6 weeks after treatment. Side-effects were scored on a standard questionnaire. RESULTS: Three patients were lost to follow-up. In the 'intention to treat' analysis 37 (92.5%) of 40 patients in group 1 were cured compared with 20 (55.6%) of 36 patients in group 2 (P < 0.001). The difference in efficacy was 36.9% (95% confidence interval 18.7-55.1%). Side-effects were fewer and milder in group 2, but all patients in both groups were able to complete the course of treatment. CONCLUSION: Dual therapy is significantly less effective in curing H. pylori infection in peptic ulcer patients than quadruple therapy. No patients were intolerant to either treatment. On the basis of the low efficacy of dual therapy, we believe that this therapy should not be used as a first-line treatment strategy. We confirmed our previous finding that 1 week of quadruple therapy is tolerated well and that it is highly effective against metronidazole-sensitive as well as metronidazole-resistant strains of H. pylori.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Drug Therapy, Combination/therapeutic use , Helicobacter Infections/drug therapy , Peptic Ulcer/drug therapy , Adult , Aged , Aged, 80 and over , Amoxicillin/adverse effects , Amoxicillin/therapeutic use , Antacids/adverse effects , Antacids/therapeutic use , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/adverse effects , Antitrichomonal Agents/adverse effects , Antitrichomonal Agents/therapeutic use , Bismuth/adverse effects , Bismuth/therapeutic use , Drug Therapy, Combination/adverse effects , Endoscopy, Digestive System , Female , Follow-Up Studies , Helicobacter Infections/etiology , Helicobacter Infections/pathology , Helicobacter pylori/drug effects , Helicobacter pylori/isolation & purification , Humans , Male , Metronidazole/adverse effects , Metronidazole/therapeutic use , Middle Aged , Omeprazole/adverse effects , Omeprazole/therapeutic use , Penicillins/adverse effects , Penicillins/therapeutic use , Peptic Ulcer/microbiology , Peptic Ulcer/pathology , Prospective Studies , Tetracycline/adverse effects , Tetracycline/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...